藤梨根提取物对人胃癌MKN-45细胞增殖及凋亡的影响  

Effect of Radix Actinidiae extractive on anti-proliferation and pro-apoptosis in human gastric cancer MKN-45 cell line in vitro

作　　者：附舰[1] 陈光伟[2] 刘理礼[1] 闵婕[1] 王宏[1] 张贺龙[1] 

机构地区：[1]第四军医大学唐都医院肿瘤科,陕西西安710038 [2]陕西中医学院附属医院肿瘤科,陕西咸阳712000

出　　处：《现代肿瘤医学》2011年第1期20-22,共3页Journal of Modern Oncology

摘　　要：目的:探讨太白山藤梨根提取物(Radix Actinidiae extractive,RAE)在体外对胃癌MKN-45细胞增殖与凋亡的影响。方法:用0.01-100μg/ml浓度范围内的RAE和胃癌MKN-45细胞共培养24、48、72、96小时,采用MTT法检测RAE对MKN-45细胞增殖的影响;用流式细胞仪检测其对MKN-45细胞凋亡及细胞周期分布的影响;DNA琼脂糖凝胶电泳检测细胞凋亡。结果:RAE在体外能够显著抑制胃癌MKN-45细胞的增殖,且呈现浓度和时间依赖性;RAE对胃癌细胞的作用表现为周期特异性,使细胞阻滞于G0/G1期,进一步诱导细胞凋亡。对照组凋亡率为0.53%,1μg/ml、10μg/ml、100μg/ml浓度的RAE干预胃癌细胞48小时后均出现凋亡峰,细胞凋亡率分别为3.27%、8.97%、12.6%。DNA琼脂糖凝胶电泳检测细胞凋亡,不同浓度RAE处理的细胞样品中均可看到梯形凋亡条带,并呈现浓度依赖性。结论:RAE在体外对人胃癌MKN-45细胞有显著的抑制细胞增殖及诱导细胞凋亡作用,其作用机制可能是使胃癌细胞周期阻滞于G0/G1期。Objective ：To investigate the role of Radix Actinidiae extractive （RAE）on anti -proliferation and pro -apoptosis for gastric cancer MKN-45 cell line in vitro, nethods：MKN -45 cells were exposed to different con- centrations of RAE for 24h, 48h,72h and 96h respectively. The proliferation was detected by 4 - methyl - teerazolium （MTr） ,the distribution of cell cycle and effect on apoptosis of RAE were analyzed by flow cytometry（FCM）. DNA gel electrophoresis was used to demonstrate DNA fragmentation. Results：RAE significantly inhibited the proliferation of gastric cancer cells in vitro on a dose - and time dependent manner;The result of FCM made it clear that RAE showed cell cycle specificity and arrested at G0/G1. After treating 48 hours on the gastric cancer cells with RAE, all appearance apoptosis peak, the apoptosis rates were 3.27% ,8.97%, 12.6%, compared to control group O. 53% （P 〈 0.05 ） ;DNA agorose gel electrophoresis（AGE） analysis revealed that RAE pretreatment lead to DNA fragmentation on a dose -dependent manner. Conclusion：RAE significantly inhibited the proliferation and induced apoptosis of gastric cancer MKN-45 cells in vitro, which arrested cell cycle at G0/G1.

关 键 词：藤梨根提取物 MKN-45胃癌细胞 细胞周期 细胞凋亡 

分 类 号：R73-36[医药卫生—肿瘤] R735.2[医药卫生—临床医学]